Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
International Clinical Psychopharmacology|August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Clinical Pharmacology and Therapeutics|August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant DepressionEva G Katz, David Hough, Teodora Doherty, et al.
Clinical Drug Investigation|June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup AnalysisMaju Mathews, Huiling Pei, Adam Savitz, et al.
The International Journal of Neuropsychopharmacology|November 28, 2009
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyMichelle Kramer, Robert Litman, David Hough, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 9, 2016
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patientsRobert Howard, Sergi G Costafreda, Keith Karcher, et al.
Innovations in Clinical Neuroscience|September 17, 2011
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophreniaSrihari Gopal, Gahan Pandina, Rosanne Lane, et al.
Neuropsychiatric Disease and Treatment|March 14, 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European populationAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
The Annals of Pharmacotherapy|September 6, 2012
An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitateThomas R Einarson, Michiel E H Hemels, Isaac Nuamah, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 25, 2010
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaGahan Pandina, Rosanne Lane, Srihari Gopal, et al.
Schizophrenia Research|October 23, 2013
Effect of parental age on treatment response in adolescents with schizophreniaMark Opler, Dolores Malaspina, Srihari Gopal, et al.
Pageof 8